CD274 and non-small cell lung carcinoma: Atezolizumab monotherapy (IMpower110) extended OS in treatment-naïve metastatic NSCLC with high PD-L1 expression, confirming PD-L1 as an enrichment biomarker for anti-PD-(L)1 benefit [95].